114
Participants
Start Date
February 29, 2016
Primary Completion Date
August 22, 2018
Study Completion Date
October 10, 2018
Mogamulizumab + Nivolumab
i.v. administration
Baltimore
Goldsboro
Augusta
Jacksonville
Columbus
Kalamazoo
Chicago
Houston
Gilbert
Albuquerque
Los Angeles
Greenbrae
Portland
Piscataway
Philadelphia
Lead Sponsor
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
Kyowa Kirin, Inc.
INDUSTRY